Developer docs
API playgroundTry for free, no card

Search company profiles

Confo Therapeutics

Full company profile

uuid000091p

Namestring
Confo Therapeutics
Legal namestring
Confo Therapeutics NV
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersZwijnaarde, Belgium
HQ citystring
Zwijnaarde
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GPCR drug discovery, small molecule therapeutics, antibody therapeutics, metabolic disease treatments, endocrine disease therapies
Industry6 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
GPCR-targeted Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

Confo generates revenue through licensing agreements where pharmaceutical partners pay upfront fees, milestone payments tied to clinical development progress, and royalties on net sales. Example: Eli Lilly deal includes $40M upfront, up to $590M in milestones per program, and tiered royalties.

confotherapeutics.com
2Government grants
TypeManaged Services
Description

Non-dilutive funding from VLAIO (Flanders Innovation & Entrepreneurship) to support R&D efforts in drug discovery targeting Class B GPCRs for endocrine and metabolic diseases.

linkedin.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Confo Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops conformation-selective small-molecule and antibody-based therapeutics against G protein-coupled receptors (GPCRs) for metabolic and endocrine diseases. The company applies its proprietary ConfoBody®-based drug discovery platform to identify novel agonists, antagonists, inverse agonists, and allosteric modulators of class A and B GPCRs, advancing proprietary drug candidates internally and out-licensing them to global pharmaceutical companies for late-stage clinical development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 54% lower risk of obesity in humans with loss of function variants in the GPR75 gene
+3 more records
Product overview1 text field

Confo Therapeutics is a clinical-stage biotechnology company with a proprietary GPCR drug discovery platform. The company develops both small molecule and antibody-based therapeutics targeting G protein-coupled receptors (GPCRs) for metabolic and endocrine diseases. The core technology platform includes ConfoBody®, ConfoChimer®, ConfoGen®, ConfoSensor®, and ConfoStructure® technologies for discovering and developing conformation-selective GPCR modulators. The clinical pipeline includes CFTX-1554 (AT2R antagonist for peripheral pain, licensed to Eli Lilly, in Phase 2) and CFTX-2034 (SSTR5 agonist antibody for Post-Bariatric Hypoglycemia, in IND-enabling studies). Discovery programs target GPR75, GLP1R, GIPR, Amylin R, GCGR for obesity, and PTHR1 for hypoparathyroidism.

Product and service5 records
1CFTX-1554
CategoryClinical-stage small molecule drug candidate
Description

Novel angiotensin II type 2 receptor (AT2R) antagonist in Phase 2a clinical development for chronic peripheral/neuropathic pain. A non-opioid approach designed to address neuropathic pain while avoiding centrally mediated side effects such as addiction and sedation. Out-licensed worldwide to Eli Lilly, which is conducting clinical development beyond Phase 1.

2CFTX-2034
CategoryClinical-stage antibody drug candidate
Description

Antibody-based somatostatin receptor 5 (SSTR5) agonist designed to treat Post-Bariatric Hypoglycemia (PBH) and related hyperinsulinemic hypoglycemia disorders. Selectively agonizes SSTR5 to suppress insulin and incretin (e.g., GLP-1) secretion and restore glycemic control, with preclinical data supporting a long half-life suitable for once-monthly subcutaneous administration. Confo's first agonistic antibody development candidate.

3GPR75 Antagonist Program (Obesity)
CategoryDiscovery-stage small molecule program
Description

Small molecule GPR75 antagonist program for the treatment of obesity. Targets an orphan class A GPCR where loss-of-function variants in humans are associated with a 54% lower risk of obesity, positioning the program as a non-incretin, potentially disease-modifying approach to obesity. Currently in lead optimization.

4Multiple Obesity Programs (GLP1R, GIPR, Amylin R, GCGR)
CategoryDiscovery-stage multi-target obesity program
Description

Programs targeting GLP1R, GIPR, Amylin R, and GCGR receptors using agonist and antagonist approaches for obesity and related metabolic conditions. Part of Confo's multi-modality obesity strategy alongside the GPR75 program. Currently in discovery stage.

5Hypoparathyroidism Program (PTHR1)
CategoryDiscovery-stage small molecule / antibody program
Description

Discovery-stage program targeting the parathyroid hormone receptor 1 (PTHR1) with an agonist approach for the treatment of hypoparathyroidism. Currently in discovery stage.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-30
Description

Collaboration to discover novel medicines for CNS diseases targeting GPCRs.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-03-02
Description

Worldwide licensing agreement for CFTX-1554, a novel AT2R antagonist for peripheral/neuropathic pain. Confo received $40M upfront and is eligible for up to $590M in milestones per program plus tiered royalties. Confo maintains co-investment option after clinical proof-of-concept.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-30
Description

Collaborative agreement for GPCR-targeting antibody discovery using Confo's technology platform.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-12-19
Description

Early drug discovery collaboration focused on GPCR targets.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-09-26
Description

Drug discovery collaboration focused on GPCR targets for CNS diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration for GPCR-targeting antibody discovery. AbCellera's antibody discovery capabilities combined with Confo's GPCR platform technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding institute and licensor of Steyaert patents for ConfoBody® technology. Confo Therapeutics was spun out of Professor Jan Steyaert's lab at VIB and VUB in 2015.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding institute. Confo Therapeutics was spun out of Professor Jan Steyaert's lab at VUB and VIB in 2015.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Sosei Heptares
TypeDirect peer
Description

Japan/UK-based GPCR-focused structural biology drug discovery company with a comparable StaR® platform for stabilizing GPCR conformations and generating small molecules and biologics. Closest direct peer given overlapping GPCR target space, structural biology approach, and big-pharma partnership model.

TypeDirect peer
Description

US-based clinical-stage GPCR drug discovery company using native GPCR structural biology and computational tools to develop small molecules against previously undruggable GPCRs. Highly comparable on platform philosophy, GPCR focus, and modality (small molecule).

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecules for GPCR targets in metabolic and cardiovascular diseases. Directly comparable on GPCR focus, metabolic disease pipeline (obesity, diabetes-adjacent indications), and partnership-driven business model.

TypeDirect peer
Description

US-based clinical-stage company developing oral non-peptide drugs targeting GPCRs with a strong focus on endocrine diseases (acromegaly, hyperinsulinism). Comparable on GPCR mechanism, endocrine/metabolic pipeline, and clinical-stage maturity.

TypeDirect peer
Description

Swiss clinical-stage biotech focused on allosteric modulators for GPCR targets in CNS and metabolic disease. Directly comparable on GPCR-focused allosteric modulation approach and clinical-stage pipeline.

6Domain Therapeutics
TypeDirect peer
Description

French GPCR-focused biotech developing small molecules and biologics targeting CNS and immuno-oncology GPCRs. Comparable on GPCR-exclusive platform and pharma partnership model, though skewed toward CNS/immuno-oncology rather than metabolic/endocrine.

TypeEmerging player
Description

US-based clinical-stage biotech developing GPCR-targeting therapeutics for metabolic and inflammatory diseases. Comparable mechanism class and metabolic focus, but earlier-stage and narrower pipeline.

TypeEmerging player
Description

US-based clinical-stage biotech focused on developing treatments for hematological and musculoskeletal disorders with metabolic/endocrine overlap. Adjacent comparison given shared therapeutic area focus rather than direct GPCR mechanism overlap.

TypeOthers
Description

Canadian antibody discovery platform company and an active collaboration partner with Confo for GPCR-targeting antibody discovery. Comparable as an enabling platform peer rather than a direct competitor.

TypeBroad incumbent
Description

Global pharmaceutical incumbent dominating the obesity and diabetes therapeutic markets with GLP-1 franchises (semaglutide). Sets competitive benchmarks for any GPCR-targeted metabolic entrant, including Confo's obesity pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Confo Therapeutics

GPCR-targeted Therapeuticsconfotherapeutics.com

Confo Therapeutics firmographics

Firmographics
Name
Confo Therapeutics
Legal name
Confo Therapeutics NV
Website
https://confotherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Confo Therapeutics industry classification

Industry
Product category
GPCR-targeted Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • GPCR drug discovery
  • Small molecule therapeutics
  • Antibody therapeutics
  • Metabolic disease treatments
  • Endocrine disease therapies

Where Confo Therapeutics is headquartered

Location

Headquarters

HQ city
Zwijnaarde
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Confo Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing and milestone payments: Confo generates revenue through licensing agreements where pharmaceutical partners pay upfront fees, milestone payments tied to clinical development progress, and royalties on net sales. Example: Eli Lilly deal includes $40M upfront, up to $590M in milestones per program, and tiered royalties.
  2. Government grants: Non-dilutive funding from VLAIO (Flanders Innovation & Entrepreneurship) to support R&D efforts in drug discovery targeting Class B GPCRs for endocrine and metabolic diseases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Confo Therapeutics product offering

Product offering

Core offering

Confo Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops conformation-selective small-molecule and antibody-based therapeutics against G protein-coupled receptors (GPCRs) for metabolic and endocrine diseases. The company applies its proprietary ConfoBody®-based drug discovery platform to identify novel agonists, antagonists, inverse agonists, and allosteric modulators of class A and B GPCRs, advancing proprietary drug candidates internally and out-licensing them to global pharmaceutical companies for late-stage clinical development and commercialization.

Product overview

Confo Therapeutics is a clinical-stage biotechnology company with a proprietary GPCR drug discovery platform. The company develops both small molecule and antibody-based therapeutics targeting G protein-coupled receptors (GPCRs) for metabolic and endocrine diseases. The core technology platform includes ConfoBody®, ConfoChimer®, ConfoGen®, ConfoSensor®, and ConfoStructure® technologies for discovering and developing conformation-selective GPCR modulators. The clinical pipeline includes CFTX-1554 (AT2R antagonist for peripheral pain, licensed to Eli Lilly, in Phase 2) and CFTX-2034 (SSTR5 agonist antibody for Post-Bariatric Hypoglycemia, in IND-enabling studies). Discovery programs target GPR75, GLP1R, GIPR, Amylin R, GCGR for obesity, and PTHR1 for hypoparathyroidism.

Differentiator

Problem solved

Functional benefit

Products and services

  • CFTX-1554 Novel angiotensin II type 2 receptor (AT2R) antagonist in Phase 2a clinical development for chronic peripheral/neuropathic pain. A non-opioid approach designed to address neuropathic pain while avoiding centrally mediated side effects such as addiction and sedation. Out-licensed worldwide to Eli Lilly, which is conducting clinical development beyond Phase 1.
  • CFTX-2034 Antibody-based somatostatin receptor 5 (SSTR5) agonist designed to treat Post-Bariatric Hypoglycemia (PBH) and related hyperinsulinemic hypoglycemia disorders. Selectively agonizes SSTR5 to suppress insulin and incretin (e.g., GLP-1) secretion and restore glycemic control, with preclinical data supporting a long half-life suitable for once-monthly subcutaneous administration. Confo's first agonistic antibody development candidate.
  • GPR75 Antagonist Program (Obesity) Small molecule GPR75 antagonist program for the treatment of obesity. Targets an orphan class A GPCR where loss-of-function variants in humans are associated with a 54% lower risk of obesity, positioning the program as a non-incretin, potentially disease-modifying approach to obesity. Currently in lead optimization.
  • Multiple Obesity Programs (GLP1R, GIPR, Amylin R, GCGR) Programs targeting GLP1R, GIPR, Amylin R, and GCGR receptors using agonist and antagonist approaches for obesity and related metabolic conditions. Part of Confo's multi-modality obesity strategy alongside the GPR75 program. Currently in discovery stage.
  • Hypoparathyroidism Program (PTHR1) Discovery-stage program targeting the parathyroid hormone receptor 1 (PTHR1) with an agonist approach for the treatment of hypoparathyroidism. Currently in discovery stage.

Quantifiable outcome

  • 54% lower risk of obesity in humans with loss of function variants in the GPR75 gene
  • +3 more outcomes

Companies that use Confo Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Confo Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Confo Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Daiichi SankyocoreStrategic or Co-development Partner · 30 March 2023Collaboration to discover novel medicines for CNS diseases targeting GPCRs.
  • Eli Lilly and CompanycoreOEM/ Whitelabel/ Licensing Partner · 2 March 2023Worldwide licensing agreement for CFTX-1554, a novel AT2R antagonist for peripheral/neuropathic pain. Confo received $40M upfront and is eligible for up to $590M in milestones per program plus tiered royalties. Confo maintains co-investment option after clinical proof-of-concept.
  • RegeneroncoreStrategic or Co-development Partner · 30 November 2021Collaborative agreement for GPCR-targeting antibody discovery using Confo's technology platform.
  • RocheminorStrategic or Co-development Partner · 19 December 2017Early drug discovery collaboration focused on GPCR targets.
  • LundbeckminorStrategic or Co-development Partner · 26 September 2017Drug discovery collaboration focused on GPCR targets for CNS diseases.
  • AbCelleracoreStrategic or Co-development PartnerResearch collaboration for GPCR-targeting antibody discovery. AbCellera's antibody discovery capabilities combined with Confo's GPCR platform technology.
  • VIB (Flanders Institute of Biotechnology)coreStrategic or Co-development PartnerFounding institute and licensor of Steyaert patents for ConfoBody® technology. Confo Therapeutics was spun out of Professor Jan Steyaert's lab at VIB and VUB in 2015.
  • Vrije Universiteit Brussel (VUB)coreStrategic or Co-development PartnerFounding institute. Confo Therapeutics was spun out of Professor Jan Steyaert's lab at VUB and VIB in 2015.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Confo Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sosei Heptares: Japan/UK-based GPCR-focused structural biology drug discovery company with a comparable StaR® platform for stabilizing GPCR conformations and generating small molecules and biologics. Closest direct peer given overlapping GPCR target space, structural biology approach, and big-pharma partnership model.
  • Septerna: US-based clinical-stage GPCR drug discovery company using native GPCR structural biology and computational tools to develop small molecules against previously undruggable GPCRs. Highly comparable on platform philosophy, GPCR focus, and modality (small molecule).
  • Structure Therapeutics: Clinical-stage biotech developing oral small molecules for GPCR targets in metabolic and cardiovascular diseases. Directly comparable on GPCR focus, metabolic disease pipeline (obesity, diabetes-adjacent indications), and partnership-driven business model.
  • Crinetics Pharmaceuticals: US-based clinical-stage company developing oral non-peptide drugs targeting GPCRs with a strong focus on endocrine diseases (acromegaly, hyperinsulinism). Comparable on GPCR mechanism, endocrine/metabolic pipeline, and clinical-stage maturity.
  • Addex Therapeutics: Swiss clinical-stage biotech focused on allosteric modulators for GPCR targets in CNS and metabolic disease. Directly comparable on GPCR-focused allosteric modulation approach and clinical-stage pipeline.
  • Domain Therapeutics: French GPCR-focused biotech developing small molecules and biologics targeting CNS and immuno-oncology GPCRs. Comparable on GPCR-exclusive platform and pharma partnership model, though skewed toward CNS/immuno-oncology rather than metabolic/endocrine.

Emerging players

  • Escient Pharmaceuticals: US-based clinical-stage biotech developing GPCR-targeting therapeutics for metabolic and inflammatory diseases. Comparable mechanism class and metabolic focus, but earlier-stage and narrower pipeline.
  • Keros Therapeutics: US-based clinical-stage biotech focused on developing treatments for hematological and musculoskeletal disorders with metabolic/endocrine overlap. Adjacent comparison given shared therapeutic area focus rather than direct GPCR mechanism overlap.

Others

  • AbCellera Biologics: Canadian antibody discovery platform company and an active collaboration partner with Confo for GPCR-targeting antibody discovery. Comparable as an enabling platform peer rather than a direct competitor.

Broad incumbents

  • Novo Nordisk: Global pharmaceutical incumbent dominating the obesity and diabetes therapeutic markets with GLP-1 franchises (semaglutide). Sets competitive benchmarks for any GPCR-targeted metabolic entrant, including Confo's obesity pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Confo Therapeutics social profiles

Digital presence

Confo Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Confo Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Confo Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Confo Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Confo Therapeutics

What does Confo Therapeutics do?

Confo Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops conformation-selective small-molecule and antibody-based therapeutics against G protein-coupled receptors (GPCRs) for metabolic and endocrine diseases. The company applies its proprietary ConfoBody®-based drug discovery platform to identify novel agonists, antagonists, inverse agonists, and allosteric modulators of class A and B GPCRs, advancing proprietary drug candidates internally and out-licensing them to global pharmaceutical companies for late-stage clinical development and commercialization.

Is Confo Therapeutics a public or private company?

Confo Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Confo Therapeutics founded?

Confo Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Confo Therapeutics based?

Confo Therapeutics is headquartered in Zwijnaarde, Belgium, in the Europe region.

How does Confo Therapeutics make money?

Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are government grants.

Who are Confo Therapeutics's main competitors?

Direct peers on record are Sosei Heptares, Septerna, Structure Therapeutics, Crinetics Pharmaceuticals, Addex Therapeutics and Domain Therapeutics. Emerging players are Escient Pharmaceuticals and Keros Therapeutics. AbCellera Biologics is listed as an others. Novo Nordisk is listed as a broad incumbent.

Does Confo Therapeutics have an API?

No public API is recorded for Confo Therapeutics.

What industry is Confo Therapeutics in?

Confo Therapeutics's product category is GPCR-targeted Therapeutics. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireConfo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026Confo Therapeutics announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody candidate for post-bariatric hypoglycemia, at the ENDO 2026 conference in Chicago. The data demonstrated dose-dependent suppression of insulin and GLP-1 secretion resulting in improved glycemic control, along with a selective pharmacology profile and long half-life supporting once-monthly subcutaneous administration. The company plans to advance CFTX-2034 through IND-enabling studies toward Phase 1 clinical development, with no approved therapies currently existing for PBH.GlobeNewswireConfo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554Confo Therapeutics announced that Eli Lilly has initiated dosing in a Phase 2a clinical trial for CFTX-1554, a novel angiotensin II type 2 receptor (AT2R) antagonist being developed for chronic peripheral pain. The candidate is the first to advance to Phase 2 clinical development using Confo's proprietary technology platform, marking a significant milestone in the company's evolution. Under a 2023 worldwide licensing agreement, Confo received a $40 million upfront payment and is eligible for up to $590 million in potential milestone payments plus tiered royalties.GlobeNewswireConfo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554Confo Therapeutics announced that first patients were dosed in a Phase 2a trial of CFTX-1554, a novel AT2R antagonist for chronic pain, developed with Eli Lilly. The licensing agreement includes a $40 million upfront payment and up to $590 million in potential milestone payments. The trial evaluates efficacy, safety, and tolerability.GlobeNewswireConfo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric HypoglycemiaConfo Therapeutics selected CFTX-2034, an SSTR5 agonist antibody, as its first antibody drug candidate for post-bariatric hypoglycemia. The company will advance it through IND-enabling studies, building on its prior out-licensing of CFTX-1554 to Eli Lilly.BioSpaceConfo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric HypoglycemiaConfo Therapeutics has selected CFTX-2034, an SSTR5 agonist antibody, as its first agonistic antibody development candidate for Post-Bariatric Hypoglycemia, a serious metabolic condition with no approved treatments that can develop after weight loss surgery. The candidate was selected based on robust preclinical data demonstrating high potency, selectivity, and a favorable pharmacokinetic and safety profile, and the company is now advancing through IND-enabling studies toward clinical trials. The milestone builds on Confo's track record, including its prior program CFTX-1554 which was successfully out-licensed to Eli Lilly in 2023.VIB.BEConfo Therapeutics – Unlocking the power of GPCRsConfo Therapeutics partnered its clinical-stage pain program CFTX-1554 with Eli Lilly, generating non-dilutive capital and validating its proprietary GPCR discovery platform. The company subsequently completed a €60 million Series B funding round in summer 2024 to advance its broader pipeline of obesity and endocrine disease programs.GlobeNewswireConfo Therapeutics Awarded VLAIO Grant for Development of Ultra-Long-Acting Antibody-Based GPCR Therapeutics in Endocrine and Metabolic ConditionsConfo Therapeutics secured a EUR 1 million grant from VLAIO to advance ultra-long-acting antibody-based GPCR therapeutics for metabolic and endocrine conditions. The 2-year funding will support bi- and multi-specific antibody formats on its proprietary platform, aiming to improve efficacy over peptide-based treatments.GlobeNewswireConfo Therapeutics Awarded VLAIO Grant for Development of Ultra-Long-Acting Antibody-Based GPCR Therapeutics in Endocrine and Metabolic ConditionsConfo Therapeutics secured a EUR 1 million grant from VLAIO to advance ultra-long-acting antibody-based GPCR therapeutics for metabolic and endocrine conditions. The 2-year funding will support bi- and multi-specific antibody formats on its proprietary platform, aiming to overcome limitations of peptide-based treatments.YahooConfo Therapeutics Awarded VLAIO Grant for Development of Ultra-Long-Acting Antibody-Based GPCR Therapeutics in Endocrine and Metabolic ConditionsConfo Therapeutics secured a EUR 1 million grant from VLAIO to advance ultra-long-acting antibody-based GPCR therapeutics for metabolic and endocrine conditions. The 2-year funding will support bi- and multi-specific antibody formats on its proprietary platform, aiming to improve efficacy over peptide-based treatments.